Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Journal of Hepatology

• Publication date

  2011-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jhep.2010.08.029PMID 21145810
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mathematical modelling of hepatitis C treatment for injecting drug users.

  2011cited by this paper
• Telaprevir for previously treated chronic HCV infection.

  2010cited by this paper
• Can hepatitis C virus prevalence be used as a measure of injection-related human immunodeficiency virus risk in populations of injecting drug users? An ecological analysis.

  2010cited by this paper
• Survival and cessation in injecting drug users: prospective observational study of outcomes and effect of opiate substitution treatment

  2010cited by this paper
• Effective treatment of injecting drug users with recently acquired hepatitis C virus infection.

  2010cited by this paper
• Optimal targeting of Hepatitis C virus treatment among injecting drug users to those not enrolled in methadone maintenance programs.

  2010cited by this paper
• The Impact of Needle and Syringe Programs on HIV and HCV Transmissions in Injecting Drug Users in Australia: A Model-Based Analysis

  2009cited by this paper
• The primary prevention of hepatitis C among injecting drug users

  2009cited by this paper
• Assessing IDU prevalence and health consequences (HCV, overdose and drug-related mortality) in a primary care trust: implications for public health action.

  2009cited by this paper
• Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program.

  2009cited by this paper
• Community‐based treatment for chronic hepatitis C in drug users: high rates of compliance with therapy despite ongoing drug use

  2009cited by this paper
• Hepatitis C treatment for injection drug users: a review of the available evidence.

  2009cited by this paper
• Hepatitis C Infection Among Injecting Drug Users in England and Wales (1992–2006): There and Back Again?

  2009cited by this paper
• Estimating hepatitis C prevalence in England and Wales by synthesizing evidence from multiple data sources. Assessing data conflict and model fit.

  2008cited by this paper
• Increasing the uptake of hepatitis C virus testing among injecting drug users in specialist drug treatment and prison settings by using dried blood spots for diagnostic testing: a cluster randomized controlled trial

  2008cited by this paper
• Injecting drug users with chronic hepatitis C: should they be offered antiviral therapy?

  2008cited by this paper
• Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C : a systematic review and economic evaluation

  2007cited by this paper
• Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation.

  2007cited by this paper
• Hepatitis C virus (HCV) prevalence, and injecting risk behaviour in multiple sites in England in 2004

  2007cited by this paper
• Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users

  2007cited by this paper
• Incidence of heroin use in Zurich, Switzerland: a treatment case register analysis.

  2006cited by this paper
• 578 Uptake of hepatitis C virus (HCV) treatment among injection drug users (IDUS) in Vancouver, Canada

  2006cited by this paper
• Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies

  2006cited by this paper
• A randomized controlled clinical study of lower-dose peginterferon alfa-2b in combination with ribavirin in the treatment of chronic hepatitis C

  2006cited by this paper
• Prospective evaluation of community-acquired acute-phase hepatitis C virus infection.

  2005cited by this paper
• Global epidemiology of hepatitis C virus infection.

  2005cited by this paper
• Follow-up studies of treatment for hepatitis C virus infection among injection drug users.

  2005cited by this paper
• Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users.

  2005cited by this paper
• Guidelines for the treatment of hepatitis C virus infection in injection drug users: status quo in the European Union countries.

  2005cited by this paper
• Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon

  2003cited by this paper
• Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse

  2003cited by this paper
• Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load

  2003cited by this paper
• Protection against persistence of hepatitis C.

  2002cited by this paper
• Prevalence of hepatitis C among injectors in Scotland 1989–2000: declining trends among young injectors halt in the late 1990s

  2002cited by this paper
• Insights into the epidemiology, natural history and pathogenesis of hepatitis C virus infection from studies of infected donors and blood product recipients.

  2001cited by this paper
• Clinical guidelines on the management of hepatitis C

  2001cited by this paper
• Treatment of hepatitis C infection in injection drug users

  2001cited by this paper
• Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy.

  1998cited by this paper
• Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy

  1998cited by this paper

• Sociodemographic and behavioral characteristics of older people with HIV in Almaty City, Kazakhstan: A cross-sectional study

  2025influential citation
• MINMON-J: a hybrid implementation pilot study evaluating a low-barrier hepatitis C treatment model in a jail setting

  2025cites this paper
• A Game-Theoretic Model of Optimal Clean Equipment Usage to Prevent Hepatitis C Among Injecting Drug Users

  2025cites this paper
• Using modelling and public health surveillance data to evidence progress towards the WHO incidence target for hepatitis C elimination in people who inject drugs - a review of complementary approaches in the United Kingdom.

  2025cites this paper
• Experience and challenges delivering hepatitis C virus treatment for people who inject drugs in Kenya

  2024cites this paper
• Evaluating the effect of direct-acting antiviral agent treatment scale-up on Hepatitis C virus prevalence among people who inject drugs in UK.

  2024cites this paper
• Modeling the impact of the COVID-19 pandemic on achieving HCV elimination amongst young and unstably housed people who inject drugs in San Francisco

  2024cites this paper
• Hepatitis C infection seroprevalence in pregnant women worldwide: a systematic review and meta-analysis

  2023cites this paper
• Modelling the contribution of incarceration and public health oriented drug law reform to HCV transmission and elimination among PWID in Tijuana, Mexico.

  2022cites this paper
• Evaluating the power of the causal impact method in observational studies of HCV treatment as prevention

  2021cites this paper
• Hepatitis B, Hepatitis C, tuberculosis and sexually-transmitted infections among HIV positive patients in Kazakhstan

  2021cites this paper
• Allocating treatment resources for hepatitis C in the UK: a constrained optimization modelling approach

  2021cites this paper
• Epidemiology of Hepatitis C Virus: People Who Inject Drugs and Other Key Populations

  2021cites this paper
• Fecaloma - A Common Problem, Uncommon Dimensions.

  2021cites this paper
• Paper microfluidic implementation of loop mediated isothermal amplification for early diagnosis of hepatitis C virus

  2021cites this paper
• The Changing Epidemiology of Hepatitis C Virus Infection in the United States During the Years 2010 to 2018.

  2021cites this paper
• Taxonomy of Mathematical Modeling Studies for Hepatitis C Among Injection Drug Users

  2021cites this paper
• Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017

  2020cites this paper
• Antibody avidity-based approach to estimate population-level incidence of hepatitis C.

  2020cites this paper
• Intrahepatic Cholangiocarcinoma in a Patient with Hepatitis C: A Cautionary Tale.

  2020cites this paper
• Per-Contact Infectivity of Hepatitis C Virus Acquisition in Association With Receptive Needle Sharing Exposures in a Prospective Cohort of Young Adult People who Inject Drugs in San Francisco, California

  2020cites this paper
• Innovations in Hepatitis C Screening and Treatment

  2020cites this paper
• UNM Digital Repository UNM Digital Repository CAN A SEX BIAS BE A GOOD THING: MODELING SPONTANEOUS CAN A SEX BIAS BE A GOOD THING: MODELING SPONTANEOUS CLEARANCE AND SEXUAL SUSCEPTIBILITY IN HCV CLEARANCE AND SEXUAL SUSCEPTIBILITY IN HCV

  2020cites this paper
• Perceptions and concerns of hepatitis C reinfection following prison-wide treatment scale-up: Counterpublic health amid hepatitis C treatment as prevention efforts in the prison setting.

  2020cites this paper
• The role of social capital in facilitating hepatitis C treatment scale-up within a treatment-as-prevention trial in the male prison setting.

  2020cites this paper
• The health impact of delaying direct‐acting antiviral treatment for chronic hepatitis C: A decision‐analytic approach

  2020cites this paper
• Viral Hepatitis-HIV Co-Infection and their associated factors in Negeri Sembilan-a cross sectional study from HIV Case Registry

  2020cites this paper
• Colocalization in Hepatitis C Virus Infection Care: The Role of Opioid Agonist Therapy Clinics

  2020cites this paper
• Prevalence and high risk behaviours associated with HCV testing among people who inject drugs: a systematic review and Meta-analysis

  2020cites this paper
• EASL recommendations on treatment of hepatitis C - Final update of the series.

  2020cites this paper
• The status of hepatitis C virus infection among people who inject drugs in the Middle East and North Africa

  2020cites this paper
• Modeling indicates efficient vaccine-based interventions for the elimination of hepatitis C virus among persons who inject drugs in metropolitan Chicago.

  2019cites this paper
• Correlates of subjective hepatitis C knowledge among clinical staff in US drug treatment programs

  2019cites this paper
• Hepatitis C transmission in young people who inject drugs: Insights using a dynamic model informed by state public health surveillance.

  2019cites this paper
• Prioritising Hepatitis C treatment in people with multiple injecting partners maximises prevention: a real-world network study.

  2019cites this paper
• Mathematical modeling of hepatitis c virus (HCV) prevention among people who inject drugs: A review of the literature and insights for elimination strategies.

  2019cites this paper
• HCV point‐of‐care screening programme and treatment options for people who use drugs in a metropolitan area of Southern Italy

  2019cites this paper
• Nickbakhsh, S., McLauchlan, J. and Leitch, E. C. M. (2018) Evaluating “treatment as prevention” on the road to hepatitis C virus

  2019cites this paper
• HCV incidence is associated with injecting partner age and HCV serostatus mixing in young adults who inject drugs in San Francisco

  2019cites this paper
• Age-related Differences in Past or Present HCV Infection among People Who Inject Drugs - National HIV Behavioral Surveillance, Eight U.S Cities, 2015.

  2019cites this paper
• Antivirals

  2019cites this paper
• Prevalence and burden of HBV co‐infection among people living with HIV: A global systematic review and meta‐analysis

  2019cites this paper
• Opioid epidemic and liver disease

  2019cites this paper
• Randomised controlled trial conducted in injecting equipment provision sites to compare the effectiveness of different hepatitis C treatment regimens in people who inject drugs: A Direct obserVed therApy versus fortNightly CollEction study for HCV treatment—ADVANCE HCV protocol study

  2019cites this paper
• Hepatitis C: Is eradication possible?

  2019cites this paper
• A dynamic model and some strategies on how to prevent and control hepatitis c in mainland China

  2019cites this paper
• The cost-effectiveness of an HCV outreach intervention for at-risk populations in London, UK

  2019cites this paper
• Modelling the potential prevention benefits of a treat‐all hepatitis C treatment strategy at global, regional and country levels: A modelling study

  2019cites this paper
• Web Annex 4 . Modelling analyses

  2018cites this paper
• Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection

  2018cites this paper
• Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe.

  2018influential citation
• Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV , hepatitis C and hepatitis B

  2018cites this paper
• The Relation between Interstitial Lung Disease and Chronic HCV Infection

  2018cites this paper
• Treatment of Chronic Hepatitis C in Patients Receiving Opioid Agonist Therapy: A Review of Best Practice.

  2018cites this paper
• EASL Recommendations on Treatment of Hepatitis C 2018.

  2018cites this paper
• Screening en preventie

  2018cites this paper
• Dépistage et prévention

  2018cites this paper
• Approaches for simplified HCV diagnostic algorithms

  2018cites this paper
• Direct-acting antivirals and chronic hepatitis C: towards elimination

  2018cites this paper
• Understanding facilitators and barriers of direct‐acting antiviral therapy for hepatitis C virus infection in prison

  2018cites this paper
• Feedback control of an HBV model based on ensemble kalman filter and differential evolution.

  2018cites this paper
• High response and re‐infection rates among people who inject drugs treated for hepatitis C in a community needle and syringe programme

  2018cites this paper
• ‘Fighting a losing battle’: prisoners’ perspectives of treatment as prevention for hepatitis C with inadequate primary prevention measures

  2018cites this paper
• Hepatitis C Virus Elimination in the Human Immunodeficiency Virus-Coinfected Population: Leveraging the Existing Human Immunodeficiency Virus Infrastructure.

  2018cites this paper
• Previous incarceration impacts access to hepatitis C virus (HCV) treatment among HIV‐HCV co‐infected patients in Canada

  2018cites this paper
• Modelling the impact of a national scale‐up of interventions on hepatitis C virus transmission among people who inject drugs in Scotland

  2018cites this paper
• The removal of DAA restrictions in Europe - One step closer to eliminating HCV as a major public health threat.

  2018cites this paper
• Factors associated with HCV test uptake in heroin users entering substitution treatment in Greece

  2018cites this paper
• Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework

  2018cites this paper
• Determinants of hepatitis C antiviral effectiveness awareness among people who inject drugs in the direct-acting antiviral era.

  2018cites this paper
• Hepatitis C

  2018cites this paper
• Establishing the cascade of care for hepatitis C in England—benchmarking to monitor impact of direct acting antivirals

  2018cites this paper
• Hepatitis C virus prevention and care for drug injectors: the French approach

  2018cites this paper
• University of Dundee Modelling the impact of a national scale-up of interventions on hepatitis C virus transmission among people who inject drugs in Scotland Fraser,

  2018cites this paper
• Hepatitis C Virus (HCV) Treatment as Prevention: Epidemic and Cost-Effectiveness Modeling

  2017cites this paper
• Importance and Contribution of Community, Social, and Healthcare Risk Factors for Hepatitis C Infection in Pakistan.

  2017cites this paper
• Modelling the impact of incarceration and prison-based HCV treatment on HCV transmission among people who inject drugs in Scotland

  2017cites this paper
• Hepatitis C disease transmission and treatment uptake: impact on the cost-effectiveness of new direct-acting antiviral therapies

  2017cites this paper
• The impact of HCV therapy in a high HIV-HCV prevalence population: A modeling study on people who inject drugs in Ho Chi Minh City, Vietnam

  2017cites this paper
• Continuum of Care for Hepatitis C Virus Among Patients Diagnosed in the Emergency Department Setting

  2017cites this paper
• Elimination of HCV as a public health concern among people who inject drugs by 2030 – What will it take to get there?

  2017cites this paper
• Insights into Hepatitis C Transmission in Young Persons who Inject Drugs: Results From a Dynamic Modeling Approach Informed by State-Level Public Health Surveillance Data

  2017cites this paper
• Prioritization of HCV treatment in the direct-acting antiviral era: An evaluation.

  2017cites this paper
• ANALYSIS OF HEPATITIS C VIRUS (HCV) EPIDEMIOLOGY AMONG YOUNG PRESCRIPTION OPIOD USERS IN RHODE ISLAND, AND MODELLING OF HCV TREATMENT SCALE-UP. By AYORINDE SOIPE

  2017cites this paper
• Modelling the impact of incarceration and prison-based HCV treatment on HCV transmission among people who inject drugs in Scotland

  2017cites this paper
• Targeted direct-acting antiviral treatment for chronic hepatitis C: A financial reality or an obstacle to elimination?

  2017cites this paper
• Strategies for the treatment of Hepatitis C in an era of interferon-free therapies: what public health outcomes do we value most?

  2017cites this paper
• Modelling the impact of incarceration and prison‐based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland

  2017cites this paper
• Recreational Drug and Psychosocial Profile in Chronic Hepatitis C Patients Seeking Antiviral Therapy.

  2017cites this paper
• Belgian experience with direct acting antivirals in people who inject drugs.

  2017cites this paper
• Treatment and primary prevention in people who inject drugs for chronic hepatitis C infection: is elimination possible in a high‐prevalence setting?

  2017cites this paper
• Evaluation of a hepatitis C education intervention with clients enrolled in methadone maintenance and needle/syringe programs in Malaysia.

  2017cites this paper
• Modeling Combination HCV Prevention among HIV-infected Men Who Have Sex With Men and People Who Inject Drugs.

  2017cites this paper
• Prevalence of hepatitis C virus infection among HIV+ men who have sex with men: a systematic review and meta-analysis

  2017cites this paper
• Treatment of HCV in persons who inject drugs: Treatment as prevention

  2017cites this paper
• Elimination of hepatitis C virus infection among PWID: The beginning of a new era of interferon-free DAA therapy.

  2017cites this paper
• Analysis of a model for hepatitis C virus transmission that includes the effects of vaccination with waning immunity

  2017cites this paper
• Trends and factors in human immunodeficiency virus and/or hepatitis C virus testing and infection among injection drug users newly entering methadone maintenance treatment in Guangdong Province, China 2006-2013: a consecutive cross sectional study

  2017cites this paper
• EASL Recommendations on Treatment of Hepatitis C 2016.

  2017cites this paper
• Prevalence of hepatitis C virus infection and its correlates in a rural area of southwestern China: a community-based cross-sectional study

  2017cites this paper